🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
26.69
+0.28 (1.06%)
Nov 18, 2026, 4:00 PM EST - Market closed

Company Description

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.

The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.

Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials.

The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye.

It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases.

The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.

Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stoke Therapeutics, Inc.
Stoke Therapeutics logo
CountryUnited States
Founded2014
IPO DateJun 19, 2019
IndustryBiotechnology
SectorHealthcare
Employees170
CEOIan Smith

Contact Details

Address:
45 Wiggins Avenue
Bedford, Massachusetts 01730
United States
Phone781 430 8200
Websitestoketherapeutics.com

Stock Details

Ticker SymbolSTOK
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$18.00
CIK Code1623526
CUSIP Number86150R107
ISIN NumberUS86150R1077
Employer ID47-1144582
SIC Code2834

Key Executives

NamePosition
Ian F. Smith A.C.A., C.P.A.Chief Executive Officer and Director
Dr. Adrian R. Krainer Ph.D.Co-Founder and Independent Director
Thomas Edward LeggettChief Financial Officer
Jason HoittChief Patient Officer
Isabel Aznarez Ph.D.Co-Founder and Chief Technology Officer
Dr. Thomas McCauley Ph.D.Chief Scientific Officer
Jonathan Allan J.D.Corporate Secretary, Compliance Officer and General Counsel
Susan WillsonVice President of Corporate Communications
Sara Den BestenChief People Officer
Dr. Barry S. Ticho FACC, M.D., Ph.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 13, 2026SCHEDULE 13G/AFiling
Nov 5, 2026SCHEDULE 13G/AFiling
Nov 3, 202610-QQuarterly Report
Oct 29, 20268-KCurrent Report
Oct 21, 2026144Filing
Oct 2, 2026144Filing
Sep 30, 2026SCHEDULE 13GFiling
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides